Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Lays Out Teva JV Impact, Confirms Blopress Transfer

This article was originally published in PharmAsia News

Executive Summary

Takeda has identified its first mature products to be transferred next April to a new joint venture with Teva, in a transaction it expects to be cash flow accretive next fiscal year despite an initial hit on revenues and operating profit.

Advertisement

Related Content

Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
Entyvio Takes Lead As Takeda Pursues Turnaround

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC088604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel